{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:33:07Z","timestamp":1773149587325,"version":"3.50.1"},"reference-count":36,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2010,9,28]],"date-time":"2010-09-28T00:00:00Z","timestamp":1285632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:p>Osteonecrosis of the jaw (ONJ), previously an entity associated with radiation therapy to the head and neck, has been observed in patients treated with bisphosphonates. Patients with metastatic breast cancer and myelomatous bone disease, commonly treated with high\u2010potency nitrogen\u2010containing bisphosphonates for a prolonged period of time, have the greatest risk of ONJ development. The reported frequency of ONJ ranges from 0.6% to 6.2% in breast cancer and from 1.7% to 15% in patients with multiple myeloma. Osteonecrosis of the jaw has also been observed in patients with other cancers such as prostate cancer and in benign bone disorders such as osteoporosis and Paget's disease in which the incidence is low. Risk factors associated with the development of ONJ include dental extractions, length of bisphosphonate treatment, and the type of bisphosphonate used. In this review, we summarize the reported incidence and risk factors associated with ONJ.<\/jats:p>","DOI":"10.1111\/j.1749-6632.2010.05771.x","type":"journal-article","created":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T02:47:28Z","timestamp":1285728448000},"page":"47-54","source":"Crossref","is-referenced-by-count":74,"title":["Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients"],"prefix":"10.1111","volume":"1218","author":[{"given":"Ana O.","family":"Hoff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bela","family":"Toth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mimi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel N.","family":"Hortobagyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert F.","family":"Gagel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,9,28]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2005.07.010"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1054\/ijom.2002.0332"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-2391(03)00720-1"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2004.02.004"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.99.132"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.8670"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.2465"},{"issue":"1","key":"e_1_2_6_9_2","first-page":"S131","article-title":"ONJ in patients with metastatic breast cancer","volume":"88","author":"Van Poznak C.H.","year":"2004","journal-title":"Breast Cancer Res. Treat."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-033571"},{"key":"e_1_2_6_11_2","first-page":"450","article-title":"The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates","volume":"63","author":"Kraj M.","year":"2006","journal-title":"Acta Pol. Pharm."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi206"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190600977690"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06230.x"},{"key":"e_1_2_6_15_2","first-page":"968","article-title":"ONJ in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos M.A.","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm370"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.080205"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2007-0159"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.06.070"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-009-0047-9"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24119"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.11.029"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199612123352401"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.3.846"},{"key":"e_1_2_6_25_2","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer and osteolytic lesions of multiple myeloma: a phase III, double\u2010blind, comparative trial","volume":"7","author":"Rosen L.S.","year":"2001","journal-title":"Cancer J."},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.105"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.06.037"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.6.1378"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp068157"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.0707onj"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200507073530120"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/07357900802208608"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-10-200605160-00009"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-10-842"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djm025"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404682"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.SABCS-09-22"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1749-6632.2010.05771.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1749-6632.2010.05771.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T23:29:42Z","timestamp":1697498982000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1749-6632.2010.05771.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,28]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["10.1111\/j.1749-6632.2010.05771.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1749-6632.2010.05771.x","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,28]]}}}